精华制药(002349) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the period was ¥318,266,155.87, representing a year-on-year increase of 5.16%[9] - Net profit attributable to shareholders of the listed company was -¥2,063,721.11, a decrease of 99.40% compared to the same period last year[9] - The net profit after deducting non-recurring gains and losses was ¥241,566.85, up 100.07% year-on-year[9] - The company expects a cumulative net profit of ¥8,000,000, representing a 115.26% increase compared to the previous year[33] - The company reported a significant decrease in short-term borrowings, down to ¥30,000,000.00 from ¥40,000,000.00, a reduction of 25%[57] - The net profit for the current period is CNY -23,014,110.88, compared to a net profit of CNY 25,513,988.67 in the previous period, indicating a significant decline[71] - The company's total comprehensive income for the current period is CNY -23,014,110.88, down from CNY 25,513,988.67 in the previous period[73] - The company reported a decrease in financial expenses, with interest expenses at ¥2,585,629.21, down from ¥5,095,501.36, a reduction of 49.2%[85] - The total profit for the current period is ¥56,038,261.03, compared to ¥104,854,987.81 in the previous period, indicating a decrease of 46.6%[85] Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,086,600,440.07, an increase of 4.94% compared to the end of the previous year[9] - The total liabilities decreased to CNY 571,700,941.79 from CNY 793,624,753.41, a significant reduction of approximately 28%[46] - The total equity attributable to the owners of the parent company increased to CNY 2,100,040,812.01 from CNY 1,849,906,867.35, representing an increase of about 13.5%[50] - The total current liabilities include a significant amount of short-term borrowings at 40,000,000.00[118] - The total liabilities amounted to CNY 793,624,753.41, indicating a manageable debt level relative to total assets[112] Shareholder Information - Net assets attributable to shareholders of the listed company amounted to ¥2,100,040,812.01, reflecting a growth of 13.52% year-on-year[9] - The total number of ordinary shareholders at the end of the reporting period was 39,444[13] - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., held 34.29% of the shares, totaling 286,592,160 shares[13] Cash Flow - Net cash flow from operating activities was ¥79,839,704.49, down 43.69% compared to the previous year[9] - Cash inflow from investment activities totaled ¥49.59 million, significantly up from ¥19.09 million, marking an increase of about 159.5%[94] - Cash outflow for investment activities was ¥80.87 million, down from ¥189.09 million, representing a decrease of approximately 57.5%[94] - Cash inflow from financing activities reached ¥445.82 million, compared to ¥355.41 million in the previous period, an increase of about 25.4%[94] - The ending balance of cash and cash equivalents was ¥559.64 million, a significant increase from ¥317.02 million, representing a growth of approximately 76.5%[94] Research and Development - Research and development expenses increased by 31.31% to ¥35,700,813.05, primarily due to higher R&D investments by Senxuan Pharmaceutical[21] - Research and development expenses increased significantly to ¥12,977,876.72, up from ¥9,687,756.39, representing a growth of 33.5%[59] - Research and development expenses increased to CNY 4,503,322.59 from CNY 3,184,298.59, reflecting a rise of about 41.5%[67] Investment Income - Investment income grew by 44.89% to ¥13,026,354.80, driven by increased net profits from affiliated company Jiangsu Wannianchang Pharmaceutical[21] - The company received cash from investment income amounting to ¥25,272,933.80, a 1193.79% increase, due to dividends from Senxuan Pharmaceutical[25] - Investment income for the current period is ¥29,354,725.52, significantly higher than ¥8,598,656.51 in the previous period, representing an increase of 241.5%[85] Operational Efficiency - Total operating costs decreased to ¥259,781,725.97 from ¥260,949,184.61, reflecting a slight reduction of 0.4%[59] - The company plans to continue focusing on R&D and market expansion strategies to improve profitability in future quarters[60] - The company reported a 91.24% decrease in other operating expenses to ¥266,576.84, due to less equipment being scrapped compared to the previous year[25]